CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • Childhood Cancer Awareness Month: 2021 Immunotherapy Research Updates

    This September for Childhood Cancer Awareness Month, we look at new research, new treatments, and how we…

    September 4, 2021| Gabriella Rojas
  • Childhood Cancer Awareness Month: 2020 Immunotherapy Research Updates

    This September for Childhood Cancer Awareness Month, we look at how we’re working toward a future immune…

    September 24, 2020| CRI Staff
  • Childhood Cancer Awareness Month: 2019 Immunotherapy Research Update

    For Childhood Cancer Awareness Month, we round up the latest news and research from the people changing…

    September 24, 2019| CRI Staff
  • How Immunotherapy is Impacting Pediatric Cancer

    We spoke with Susanne Baumeister, MD, about the current treatment landscape in childhood cancer, including immunotherapy and…

    September 19, 2019| Arthur N. Brodsky, PhD
  • FDA Approves First-In-Class CAR T Cell Immunotherapy for Leukemia

    Children and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL) can now receive the CD19-targeting CAR T…

    August 30, 2017| Arthur N. Brodsky, PhD
  • Pembrolizumab Approved for Children and Adults with Hard-to-Treat Hodgkin Lymphoma

    Pembrolizumab is second anti-PD-1 drug approved for adults with cHL, first for any childhood cancer

    March 15, 2017| Arthur N. Brodsky, PhD

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Donate
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute